source
- Bristol Myers ends $100M Phase 1 cancer ADC programBristol Myers Squibb announced it has discontinued development of its Phase 1 antibody-drug conjugate candidate BMS-986497/ORM-6151. The decision follows a review of early clinical data, leading t…
- CMS offers Medicare pricing program exemptions to drugmakers who add Medicaid rebatesThe Centers for Medicare & Medicaid Services (CMS) has announced that drug manufacturers can be exempted from two Medicare pricing demonstration programs. The exemption is conditional on the compan…